Rubicon Research share price
NSE: RUBICONBSE: 544578Pharmaceuticals & BiotechnologySmall Cap
Rubicon Research Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Oct 2025 · Issue price ₹485
Last close ₹1,564.00up ₹54.40 (3.60%)BSE ₹1,565.05
Share price at the NSE close on 28 Oct 2026. Previous close ₹1,509.60.
28 Oct: open ₹1,485.00, high ₹1,578.50, low ₹1,484.90
52-week range of traded prices to 28 Oct 2026
₹590.95Low, 28 Oct 2025₹1,899.00High, 28 Aug 2026
- Under NSE's long-term additional surveillance, stage I, on the list for 28 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Next results date: the board meets on 5 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹25,889 Cr429th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 89.83
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 20.09
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.10%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the latest balance sheet's; the one a year before is not on record.
- 22.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 25.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.20
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 1,26,57245.7% delivered
About Rubicon Research
Rubicon Research is a specialty pharmaceutical company that develops and sells medicines, with a focus on regulated markets, particularly the United States. Its portfolio includes oral solids, liquids, nasal, ophthalmic, injectable and topical formulations, as well as drug-device combinations. In the United States it owns Validus Pharmaceuticals, a New Jersey-based marketer of brand-name products that specialises in CNS (central nervous system) and CVS (cardiovascular) therapies.
Research and development runs from two centres, one in Thane, Maharashtra, and one in Ontario, Canada, which works on nasal and inhalation products. A logistics and distribution unit in East Brunswick, New Jersey, is licensed to distribute prescription pharmaceuticals across 45 US states. A subsidiary, Rubicon Consumer Healthcare, develops self-care products for the Indian market.
Manufacturing sites are at Ambernath and Satara in Maharashtra, at Pithampur, Indore, in Madhya Pradesh, and at East Brunswick in New Jersey. The Satara site makes oral liquids.
Rubicon was founded in 1999 as an independent product development company. Its acquisitions include Impopharma Canada Limited, which added nasal and pulmonary drug development, Validus Pharmaceuticals, the logistics company AimRx 3PL, the Pithampur plant from Alkem Laboratories in June 2025, and an 85% stake in Arinna Lifesciences, an India based company, in April 2026. It listed on BSE and NSE in October 2025. Pratibha Pilgaonkar, the Managing Director, is a promoter. A promoter is the person or group that set up a company or controls it. Parag Sancheti is Executive Director and CEO.
Written from the annual report for the year to Mar 2026, filed 14 Aug 2026 and the investor presentation.
Sources for 31 statements, each with its page
- Focus on regulated markets, particularly the United States. Annual report, page 12
- Portfolio includes oral solids, liquids, nasal, ophthalmic, injectable formulations. Annual report, page 5
- Portfolio includes liquids, nasal, ophthalmic, injectable formulations. Annual report, page 5
- Portfolio includes topical formulations. Annual report, page 5
- Validus is a New Jersey-based marketer of brand-name products. Annual report, page 5
- Validus is a marketer of brand-name products. Annual report, page 5
- Validus specialises in CNS and CVS therapies. Annual report, page 5
- Rubicon acquired Validus Pharmaceuticals. Annual report, page 5
- Two R&D centres, one in Thane, Maharashtra and one in Ontario, Canada. Annual report, page 25
- Canadian centre works on nasal and inhalation. Annual report, page 10
- East Brunswick unit does licensed distribution of prescription pharmaceuticals. Annual report, page 10
- Distribution across 45 US states. Annual report, page 10
- Rubicon Consumer Healthcare develops self-care products for the Indian market. Annual report, page 5
- Manufacturing site at Ambernath, Maharashtra. Annual report, page 9
- Manufacturing site at Satara, Maharashtra. Annual report, page 9
- Satara site makes oral liquids. Annual report, page 9
- Manufacturing site at Pithampur, Indore, Madhya Pradesh. Annual report, page 9
- Manufacturing facility in East Brunswick, New Jersey. Investor presentation, page 12
- Founded in 1999 as an independent product development company. Annual report, page 8
- Acquired Impopharma Canada Limited. Annual report, page 5
- Impopharma added nasal and pulmonary drug development. Annual report, page 5
- Acquired AimRx 3PL, a logistics company. Annual report, page 5
- Acquired Alkem Laboratories' Pithampur plant in June 2025. Annual report, page 8
- Pithampur acquisition dated June 2025. Annual report, page 8
- Acquired an 85% stake in Arinna Lifesciences. Annual report, page 5
- Arinna is an India based company. Annual report, page 8
- Arinna acquisition concluded in April 2026. Annual report, page 7
- Listed on BSE and NSE in October 2025. Annual report, page 7
- Pratibha Pilgaonkar is Managing Director. Investor presentation, page 35
- Pratibha Pilgaonkar is a promoter. Investor presentation, page 35
- Parag Sancheti is Executive Director and CEO. Investor presentation, page 35
Results
Consolidated; ₹ crore.Rubicon Research quarterly results
Quarter to Jun 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹534 Crup 3.97%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹85 Crup 10.41%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 15.9%
Revenue by quarter
Peak revenue ₹534 Cr, quarter to Jun 2026; lowest ₹352 Cr, quarter to Jun 2025
Net profit by quarter, a loss in red
| ₹ crore | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|
| Revenue | 352 | 412 | 476 | 514 | 534 |
| Net profit | 43 | 54 | 73 | 77 | 85 |
| Net margin | 12.3% | 13.1% | 15.3% | 14.9% | 15.9% |
Consolidated. The 5 quarters from Jun 2025, the first on record. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Year to Mar 2026
- Revenue
- ₹1,754 Cr
- Net profit
- ₹247 Cr
- Net margin
- 14.1%
| ₹ crore | Mar 2026 |
|---|---|
| Revenue | 1,754 |
| Net profit | 247 |
| Net margin | 14.1% |
Consolidated. Years to March. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Business segments
In the year to Mar 2026 the company reports one business segment, Pharmaceutical, which carries all its revenue.
Valuation
Today, against the company's own history.Rubicon Research PE ratio and valuation
Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
At or below today's level on 94% of 247 trading days over the last year.
LowestHighest
Its median0.00%Industry median0.49%
Mutual fund holdings
87 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 8 of the 24 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future.All 87 funds holding Rubicon Research
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 38
- AddedAdded. Funds that held more shares than at the end of the month before.
- 18
- CutCut. Funds that held fewer shares than at the end of the month before.
- 6
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 25
- Sold outSold out. Funds that held it at the end of the month before and hold none at this month's end. Sold out in the glossary
- 1
| Fund | |||
|---|---|---|---|
 Kotak Mid Cap FundKotak Mahindra Mutual Fund | 37,78,406 | 0.92% | ₹611.9 Cr |
 Motilal Oswal Small Cap FundMotilal Oswal Mutual Fund | 19,65,569 | 3.84% | ₹318.3 Cr |
 HDFC Balanced Advantage FundHDFC Mutual Fund | 17,77,052 | 0.28% | ₹287.8 Cr |
| Kotak Large & Mid Cap FundKotak Mahindra Mutual Fund | 16,56,624 | 0.88% | ₹268.3 Cr |
 SBI Multicap FundSBI Mutual Fund | 16,48,216 | 1.14% | ₹266.9 Cr |
| HDFC Flexi Cap FundHDFC Mutual Fund | 13,44,729 | 0.20% | ₹217.8 Cr |
 ICICI Prudential Flexi Cap FundICICI Prudential Mutual Fund | 12,20,104 | 0.79% | ₹197.6 Cr |
 Axis ELSS Tax Saver FundAxis Mutual Fund | 9,04,407 | 0.48% | ₹146.5 Cr |
 Bajaj Finserv Flexi Cap FundBajaj Finserv Mutual Fund | 8,76,312 | 1.66% | ₹141.9 Cr |
| Kotak Manufacture in India FundKotak Mahindra Mutual Fund | 8,33,029 | 4.31% | ₹134.9 Cr |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Promoter and insider buying and selling
Trades made since 28 Oct 2025.Rubicon Research insider trading
Bought on the marketBought on the market. The value each filer stated for its purchases on the exchange, added up; gifts, transfers and pledges are not counted. A purchase filed with no value is counted under the sum, not in it. Sold on the marketSold on the market. The value each filer stated for its sales on the exchange, added up; gifts, transfers and pledges are not counted. A sale filed with no value is counted under the sum, not in it.
- Promoters and promoter group0 purchases, 2 salesNo purchase₹2,325 CrNetNet. The value bought on the market less the value sold, over the trades whose filers stated a value.−₹2,325 Cr
- Employees1 purchase, 21 sales₹0.00 Cr₹5.32 CrNet−₹5.32 Cr2 pledges created · 1 pledge released
- Others: no market trade · 14 pledge filings of unclear kind
Bought and sold count trades on the market only. A pledge is shares given to a lender as security for a loan; a lender invokes it by selling them.
Rubicon Research competitors and peers
Pharmaceuticals, 215 listed companies, priced on 28 Oct 2026. The table lists the 8 companies closest to Rubicon Research in market cap.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Sai Life SciencesSAILIFE | 31,591 | 87.33 | 12.72 | – | – | 15.7% | 18.7% | 0.00% |
 WockhardtWOCKPHARMA | 31,091 | 76.02 | 6.29 | +18.4% | – | 8.8% | 7.4% | 0.00% |
 Piramal PharmaPPLPHARMA | 30,994 | – | 3.81 | +9.4% | – | −2.6% | 2.3% | 0.00% |
 Acutaas ChemicalsACUTAAS | 30,374 | 69.17 | 16.35 | +45.2% | +96.1% | 26.9% | 30.2% | 0.07% |
 Neuland LaboratoriesNEULANDLAB | 25,621 | 51.47 | 13.67 | +78.3% | +182.6% | 29.3% | 32.1% | 0.17% |
 Granules IndiaGRANULES | 22,926 | 34.61 | – | +24.8% | +38.1% | 15.1% | 15.1% | 0.21% |
 Shilpa MedicareSHILPAMED | 18,228 | 61.31 | 7.03 | +27.9% | +167.6% | 12.0% | 10.9% | 0.06% |
 Cohance LifesciencesCOHANCE | 18,214 | 171.45 | 4.66 | +41.2% | −58.5% | 3.8% | 3.0% | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Rubicon Research dividend history
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up. Dividend per share in the glossaryHighest ₹1.50 a share, year to Mar 2026.
| Ex-date | Type | Per share |
|---|---|---|
| 7 Aug 2026 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. Final dividend in the glossary | ₹1.50 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Rubicon Research announcements
Oct 2026
28 Oct · General Updates
27 Oct · Board meeting
9 Oct
8 Oct · Updates
Aug 2026
Rubicon Research share price by year
Each calendar year to 2025.Rubicon Research share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 680.75 | – | 742.10 | 577.25 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2025 is from its first session, 16 Oct 2025.
Recent sessions
The 9 trading days to 27 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 27 Oct 2026 | 1,500.00 | 1,533.70 | 1,486.30 | 1,509.60 | 1,514.36 | 95,467 | 49.1% |
| 26 Oct 2026 | 1,424.40 | 1,515.50 | 1,424.40 | 1,490.30 | 1,481.58 | 1,89,792 | 29.8% |
| 23 Oct 2026 | 1,435.90 | 1,436.00 | 1,390.50 | 1,424.40 | 1,414.36 | 3,83,969 | 69.2% |
| 22 Oct 2026 | 1,448.50 | 1,451.10 | 1,393.00 | 1,436.60 | 1,421.71 | 1,60,273 | 51.0% |
| 21 Oct 2026 | 1,486.70 | 1,496.70 | 1,415.80 | 1,448.50 | 1,437.09 | 3,55,437 | 70.1% |
| 19 Oct 2026 | 1,510.80 | 1,514.80 | 1,465.50 | 1,486.70 | 1,485.47 | 1,09,636 | 54.8% |
| 16 Oct 2026 | 1,477.10 | 1,544.90 | 1,468.00 | 1,508.60 | 1,515.09 | 2,12,955 | 53.5% |
| 15 Oct 2026 | 1,517.50 | 1,517.50 | 1,450.50 | 1,477.10 | 1,471.52 | 3,33,405 | 60.7% |
| 14 Oct 2026 | 1,513.90 | 1,536.00 | 1,483.40 | 1,524.70 | 1,520.69 | 1,27,836 | 56.2% |
Prices in ₹ per share as traded, not adjusted.
Company details
- NSE symbol
- RUBICON
- BSE code
- 544578
- ISIN
- INE506V01022
- Industry
- Pharmaceuticals & Biotechnology
- Website
- www.rubicon.co.in
- CIN
- U73100MH1999PLC119744
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 1999
- Registered office
- B-75, MedOne House, Road No. 33, Wagle Estate, Thane West, 400604, Maharashtra
- Share registrar
- MUFG Intime India Pvt. Ltd
- Keeps the register of shareholders and handles transfers and dividend payments
In Nifty 500, Nifty Smallcap 250, BSE SmallCap, Nifty Total Market, BSE Healthcare, Nifty500 Healthcare